20:58 , Apr 25, 2017 |  BC Extra  |  Company News

Biogen climbs as Spinraza sales top consensus

Biogen Inc. (NASDAQ:BIIB) gained $10.03 to $286.89 after it reported 1Q17 earnings that beat a consensus estimate, including stronger than expected sales of Spinraza nusinersen. The company reported $47.4 million in sales of the spinal...
07:00 , Jun 20, 2016 |  BioCentury  |  Product Development

Translating LINGO

Biogen Inc. isn't talking yet about why its anti-LINGO mAb failed a Phase II trial in the high-priority indication of multiple sclerosis, but translational researchers in the field have some ideas about knowledge gaps that...